1637P Impact of immune-related adverse events (irAEs) and survival (OS) in a cohort of MPM patients (p) treated with immunotherapy (IT)

S.M Cedres Perez,A Valdivia,J.D Assaf,P Iranzo Gomez,A Callejo,N Pardo Aranda,A.F Navarro Mendivil,A Martinez-Marti,G Molina,V Navarro,J Gonzalo,M Soleda,J Frigola,C Carbonell,R Amat,R Dienstmann,E Felip

doi:10.1016/j.annonc.2022.07.1716

1637P Impact of immune-related adverse events (irAEs) and survival (OS) in a cohort of MPM patients (p) treated with immunotherapy (IT)

S.M Cedres Perez, A Valdivia + Show 15 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1716

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: Institut Català d'Oncologia, Vall d'Hebron Institute of Oncology

#Survival Benefit Of Immunotherapy #Benefit Of Immunotherapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Studies in solid tumors reported that p treated with IT who developed irAEs presented favorable OS. CheckMate-743 trial demonstrated survival benefit of IT over chemotherapy in 1st line. In a post-hoc analysis on 52 p who discontinued treatment due to irAEs, the survival benefit was not negatively impacted. We aimed to assess the impact of irAEs and survival outcomes in our series of p treated with IT.

Full Text